2009 CANCER PROGRAM ANNUAL REPORT
As Chairman of the Children’s Hospital Cancer Committee,

I have the pleasure of presenting to you the 2009 annual report with statistical data from 2008. In 2008, Children’s Hospital provided services to more pediatric cancer patients than any other pediatric cancer center in the region. We welcomed our own Dr. Lolie Yu, Eugenie & Joseph Jones professor of pediatrics and director of the Hematopoietic and Stem Cell Transplant Program as our division chief, and greeted our new partner, Dr. Jaime Morales, from MD Anderson Cancer Center, with enthusiasm. In the spirit of service, our program has continued to thrive, grow, prosper and provide us with the opportunity to graciously serve as the leading provider for children with cancer in our great state.

Under Dr. Yu’s leadership, in 2008 we obtained FACT Accreditation (Foundation for the Accreditation of Cellular Therapy), and thereby claimed the title as the only accredited pediatric hematopoietic and stem cell transplantation program in Louisiana. In 2008, we exceeded any previously recorded transplantation rate in the state. Proudly, we celebrated the inauguration of our newly renovated pediatric hematology/oncology outpatient clinic, began to plan the implementation of a new centralized roadmap system, studied and subsequently revised our system of antibiotic delivery to our oncology patients with new fever to ensure delivery of antibiotics in 60 minutes or less. We have continued to serve our patients as members of the Children’s Oncology Group. This has ensured that a child in New Orleans has the same access to the most recent therapies, and can achieve the same cure rates as any child within the United States. With the cooperative group, we join the fight against childhood cancer to ensure that no child in the state of Louisiana has to leave home to receive cutting edge, state of the art therapies that are offered to all children with cancer throughout the United States. The physicians within our division are academicians and work not only as clinical researchers, but are members of the Louisiana State University Health Sciences Faculty in the Department of Pediatrics, The Stanley S. Scott Cancer Center and the National Marrow Donor Program.

The core of our program sits within the Children’s Hospital Cancer Committee. With the support of the committee, our program is accredited by the American College of Surgeon’s Commission on Cancer, has weekly multidisciplinary cancer conferences, a cancer registry, community outreach programs and quality improvement studies. With this dedicated group of physicians, nurses, administrators and support staff, our program is the leading state program and will continue to strive to be the best Hematology/Oncology program in the years to come.

As we approach the end of the year, we reflect on our triumphs and our sorrows, our accomplishments and targeted goals. We review the treatment and supportive care measures that we have done extremely well and continue...
to strive for excellence to save all children with cancer by ultimately finding “the cure.”

In this 2009 annual report, we remember all the children that we have had the honor and privilege to have as our patients. We certainly learn more from them about how to be better human beings than we could learn in a lifetime. Our patients are truly our heroes, and they are the reason we love what we do. It is in the spirit of hope and love that we continue to fight for the cure. This report is dedicated to our patients and the love of family, friends that they constantly teach us is the most important thing in life. We carry their stories in our hearts, and will always remember the inspiring stories they have yet to tell.

**Tammyulla Evelyn Chrisentery Singleton, MD**
Chairman, Cancer Committee
THE MISSION OF THE CANCER COMMITTEE is to monitor the care given to children with cancer and implement those ideas that will lead to improvement in that care. Since 1989, the Cancer Committee has acted under the aegis of the American College of Surgeons, Commission on Cancer (ACoS, CoC), using guidelines established by them for pediatric cancer centers in the United States. We remain an approved pediatric cancer referral center. We formally became the Center for Cancer and Blood Disorders in 2002 and have offered, in that capacity, up-to-date treatment protocols and clinical trials which provide patients with the opportunity to take advantage of the most advanced and current therapies. It also affords them the opportunity to learn of new advances as soon as they emerge.

The Cancer Committee is comprised of professionals who render care to children with cancer. Together, they embody the multidisciplinary concept of cancer treatment, i.e., taking a unified but comprehensive approach to care or “treating mind, body and soul.” As pediatric hematologists/oncologists, pediatric neurosurgeons, urologic and orthopedic surgeons, radiation oncologists, pediatric radiologists and pathologists, these professionals combine their specific outlooks to view the patient as a whole and offer suggestions and plans to improve care. Child psychiatrists, psychologists, social workers, play therapists, non-denominational pastoral workers and rehabilitation specialists also bring to the table their unique outlooks on the support of these children.

This past year, we also worked closely with organizations such as the American Cancer Society and Leukemia/Lymphoma Society. Such connections have helped us to better reach out to the community at large and initiate programs for cancer prevention and education. They have also helped us better assist families in resettling into the post-Katrina environment with its attendant stresses and exigencies. Examples of joint efforts by the Hematology/Oncology Division and these organizations have included lodging of our patients at the American Cancer Society’s Hope Lodge, the provision of a grant that provides transportation vouchers for needy parents and the Smile Program. The Smile Program is an endeavor which remains dear to our hearts; it was developed by the American Cancer Society, and is designed to enable the establishment of Big Brother/Sister-like relationships between our patients, especially those with cancer, and medical students at the Louisiana State University Health Sciences Center (LSUHSC). Such relationships have lasted, at times, beyond the tenure of the students at the medical schools; life-long bonds have been forged which sustain our children for years afterwards.

We also have been able to variably call upon the services of anesthesiology, pharmacy, cardiology, ophthalmology, nursing and laboratory services to ensure greater quality control. Nursing staff has provided special insight into the problems that sometimes develop on the unit. They have been instrumental in carrying out some key projects on patient satisfaction, infection control and analgesic administration that have allowed us to come up with creative solutions to problems seen in patient care.

The Cancer Committee also oversees clinical research activities, both those associated with our hospital and those carried out through our affilia-
tion with the Children’s Oncology Group (COG), of which we have been a member institution since 1987. COG is a national, collaborative pediatric cancer research organization, sponsored by the National Cancer Institute at the National Institutes of Health (NCI, NIH). Over 90 percent of children who are diagnosed with cancer in the United States, Canada and other countries throughout the world are enrolled in protocols for therapeutic, cancer control, epidemiology or biology trials through COG. It is our stance that a high percentage of our patients should participate in such trials in order to advance our knowledge of childhood cancer and to provide the patients with the latest advances in treatment and knowledge about the process of their diseases. It is acknowledged that clinical trial participation has been associated with improved survival overall after diagnosis of cancer.

We regularly have residents, fellows and other allied health specialists in attendance at our meetings. This provides an opportunity to educate them regarding the interactions and intricacies involved in care of children with cancer and other blood disorders. Children’s Hospital is closely affiliated with LSUHSC and is one of its major teaching hospitals, providing high-quality education to all these individuals. The environment provided by Children’s Hospital has likely influenced the career choices of the LSUHSC medical students who, in high proportion, elect to pursue a pediatric or med/peds residency. Education, in general, remains an essential goal at Children’s Hospital, with the Cancer Committee recently incorporating programs on cancer prevention trials such as the FreshStart program, a comprehensive approach to the cessation of smoking during pregnancy and after delivery. We are involved in providing information to the families of children in Louisiana through our Web site, addressing their concerns about long term environmental and toxic hazards that might be encountered upon their return to New Orleans and its environs.

We hope that this annual report of the Children’s Hospital Cancer Committee will provide you with information about the oncology and hematology services available at Children’s Hospital. Further information can be obtained by calling the Division of Hematology/Oncology at (504) 896-9740.

**Cancer Committee Members**

**Tammuella Singleton, MD,** Cancer Committee Chairman, Pediatric Hematology/Oncology

**Evans Valerie,** Physician Liaison, Pediatric Surgery

**Kishor Bhende, MD,** Hematology/Oncology

**Simone Bienvenu, RN,** Quality Assessment & Improvement

**Rachel Bufkin, CTR,** Cancer Registrar

**Kay Casey, MSW,** Social Services Department

**Randall D. Craver, MD,** Pathology/Laboratory Department

**Cheryl Fourcade,** American Cancer Society

**Renee Gardner, MD,** Hematology/Oncology

**Cherie Hadley, RN,** Hematology/Oncology

**Marie-Louise Haymon, MD,** Radiology

**Stephen Heinrich, MS, MD,** Orthopaedic Surgery

**Wendy Huval, RHIA,** Director of Medical Records

**Amy Lee,** Child Life Specialist

**Jaime Morales, MD,** Hematology/Oncology

**Cori Morrison, MD,** Hematology/Oncology

**Joseph Nadell, MD,** Neurosurgery

**Lisa Patterson, RN,** Hematology/Oncology

**Mary Perrin,** Vice-President, Hospital Operations

**Faisal Razzaqi, MD,** Hematology/Oncology

**Jay Schwab, RPh, BCNS,** Pharmacy

**Stephanie Sonnier,** Clinical Trials

**Claudette Vicks, RN,** Hematology/Oncology

**Maria Velez, MD,** Hematology/Oncology

**Lynn Winfield, RN, BSN,** Nurse Manager, 4 West

**Lolie Yu, MD,** Hematology/Oncology

**Ellen Zakris, MD,** Radiation/Oncology
Atypical Teratoid Rhabdoid Tumor (ATRT) is a highly malignant embryonal brain tumor of childhood. It is rare, accounting for approximately 2-15% of all primary central nervous system (CNS) tumors in children less than 18 years of age, and occurring more commonly in children less than 5 years (1-4). ATRT was initially described as a distinct entity in an analysis by the First National Wilms' Tumor Study cohort in 1978 (5). Subsequently it was described as a primary tumor of the CNS (6) and soft tissues with a very malignant nature and tendency for early metastasis. It is characterized by the presence of rhabdoid cells with or without sheets of fields resembling a classic primitive neuroectodermal tumor (PNET) along with characteristic immunohistochemistry and cytogenetics (Negative INI-1 expression and 22q11.2 abnormalities). Overall outcome for ATRT is poor with a median survival after diagnosis of 11 to 17 months. With a multi-modality therapeutic approach including autologous stem cell transplant and better supportive care there has been some improvement in reported survival among children older than 3 years, however the prognosis for those less than 3 years remains dismal (7).

**INTRODUCTION**

Diagnostic criteria used were the following: 1) Typical histopathological features of ATRT showing presence of rhabdoid cells characterized by prominent nucleoli, abundant pink cytoplasm, eccentric nuclei and cytoplasmic inclusions with or without sheets of fields resembling classic neuroectodermal tumors. 2) Characteristic immunohistochemistry showing positivity for vimentin, EMA, GFAP, cytokeratin and synaptophysin. 3) Absence of INI-1 expression with or without 22q11 abnormalities.

Overall survival (OS) was calculated with the end point of death or last contact with patient. Event free survival (EFS) was defined by first significant event after commencing treatment (relapse, life threatening event or complication, death). Survival functions were estimated using the Kaplan-Meir method. Survival by age at diagnosis was compared using the logrank test. Phone calls were used to track patients who had been lost to follow-up.

**RESULTS**

Out of 158 patients diagnosed with a brain tumor over a 10 year period, there were 9 children confirmed to have ATRT (5.7% of all brain tumors) (Figure 1). All of them were females. One patient also had Phelan-McDermid Syndrome, which is associated with the chromosomal deletion 22q13. Another patient was found to have a genetic form of ATRT, having had a sibling die of a rhabdoid tumor 2 years prior, and with DNA testing demonstrating the 22q11 deletion in both of them. Median age at diagnosis for all patients was 40 months (range 2 months to 14 years). Table 1 summarizes patient profiles.
Clinical Findings: The most common clinical symptoms were vomiting, weight loss and clumsiness, followed by neurological problems such as weakness, ataxia and eye deviation. Six patients had focal neurological signs including paresis or cranial nerve involvement. Frequent headaches and projectile vomiting were reported in one patient each.

Radiological Studies (Figure 2): All patients underwent brain and spine magnetic resonance imaging. These studies demonstrated markedly large tumors at diagnosis and heterogeneity with contrast enhancement in all cases. Additional findings included the presence of a cystic component, necrosis, hemorrhage and calcifications. Tumors were infratentorial in 7 patients, 5 of which were located in the posterior fossa. Three patients had spinal metastasis at diagnosis. There was no evidence of distant metastases.

Pathology: All tumors had classic histopathological findings (Figure 3). The characteristic negative INI-1 expression was also demonstrated (Figure

<table>
<thead>
<tr>
<th>No</th>
<th>Age at diagnosis</th>
<th>Sex</th>
<th>Tumor Location</th>
<th>Metastasis</th>
<th>Surgery</th>
<th>Radiation</th>
<th>Chemotherapy</th>
<th>Relapse/Progression</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2 months</td>
<td>F</td>
<td>Posterior fossa</td>
<td>Spine</td>
<td>GTR</td>
<td>Spinal, posterior fossa</td>
<td>Sarcoma-like, Intrathecal chemo</td>
<td>Stable disease</td>
<td>DOD</td>
</tr>
<tr>
<td>2</td>
<td>12 months</td>
<td>F</td>
<td>Right thalamus</td>
<td>None</td>
<td>STR 60%</td>
<td>CS</td>
<td>ICE</td>
<td>PD</td>
<td>DOD</td>
</tr>
<tr>
<td>3</td>
<td>18 months</td>
<td>F</td>
<td>Right temporal lobe</td>
<td>None</td>
<td>GTR</td>
<td>CS (at relapse)</td>
<td>ICE</td>
<td>Relapsed at 7 months</td>
<td>AND</td>
</tr>
<tr>
<td>4</td>
<td>23 months</td>
<td>F</td>
<td>Posterior fossa, 4th ventricle</td>
<td>CSF Positive</td>
<td>GTR</td>
<td>None</td>
<td>None</td>
<td>PD</td>
<td>DOD</td>
</tr>
<tr>
<td>5</td>
<td>3yr4 months</td>
<td>F</td>
<td>Left occipital lobe</td>
<td>None</td>
<td>GTR</td>
<td>CS Cyberknife-1rd relapse</td>
<td>ICE I,T-2nd relapse</td>
<td>Recurrent disease</td>
<td>AWD</td>
</tr>
<tr>
<td>6</td>
<td>4 yr</td>
<td>F</td>
<td>Midline posterior fossa</td>
<td>None</td>
<td>GTR</td>
<td>CS</td>
<td>ICE, high dose chemo with stem cell rescue</td>
<td>Relapsed at 21 months</td>
<td>UNK</td>
</tr>
<tr>
<td>7</td>
<td>4yr5 months</td>
<td>F</td>
<td>Midline post fossa, 4th ventricle vermis</td>
<td>Spine</td>
<td>NTR</td>
<td>CS</td>
<td>Tandem high dose chemo with stem cell rescue</td>
<td>None</td>
<td>DOC</td>
</tr>
<tr>
<td>8</td>
<td>4yr10 months</td>
<td>F</td>
<td>Right CP angle</td>
<td>Spine</td>
<td>NTR</td>
<td>CS</td>
<td>ICE</td>
<td>PD</td>
<td>DOD</td>
</tr>
<tr>
<td>9</td>
<td>14 yr8 months</td>
<td>F</td>
<td>Posterior fossa</td>
<td>None</td>
<td>GTR</td>
<td>CS</td>
<td>ICE</td>
<td>None</td>
<td>AND</td>
</tr>
</tbody>
</table>

AND: Alive with no disease; AWD: Alive with disease; CS: Crainiospinal; DOC: Dead of other cause; DOD: Dead of disease; GTR: Gross total resection; ICE: Ifosfamide Carboplatin Etoposide; I: Irinotecan; NTR: Near total resection; PD: Progressive disease; STR: Subtotal resection; T: Temozolamide; UNK: Outcome unknown
4). Abnormalities of chromosome 22 were seen in 2 patients. One patient had malignant cells in the cerebrospinal fluid.

**TREATMENT MODALITIES**  
Patients were offered multi-modality treatment which consisted of surgery, radiation and chemotherapy. One patient’s family opted not to treat with radiation or chemotherapy.

**Surgery:** All patients underwent surgical resection. Gross total resection was achieved in 6 out of 9 patients. Two patients had minimal residual tumor left. The other patient only had a 60% tumor resection. Post-operatively 2 patients experienced new neurological deficit, one developed paresis on the left side and another patient had significant motor deficit requiring prolonged ventilation and tracheostomy tube insertion.

**Radiation:** Seven patients received craniospinal radiation. One patient had emergency spinal radiation followed by conformal posterior fossa irradiation 3 months later. Nausea, vomiting and weight loss were the most common side effects. A 6-months-old patient, who received radiation to the posterior fossa, developed post-radiation necrosis with significant neurological deterioration, which responded minimally to steroid treatment.

**Chemotherapy:** Six patients were initially treated with ifosfamide/carboplatin/etoposide (ICE) chemotherapy. One patient was treated with four courses of high dose chemotherapy with cisplatin, vincristine and cyclo-
phosphamide followed by autologous stem cell rescue. Another patient was treated with sarcoma-like therapy and intrathecal chemotherapy (8).

**Response to treatment:** Five out of 8 patients (62%) went into remission after initial chemotherapy and radiation. Two patients did not respond to initial treatment. One patient had a partial response in the form of resolution of intracranial tumor with stable spinal disease; however family opted to withdraw treatment after significant morbidity with radiation. Recurrence or progression of disease was seen in 6 patients overall.

At 2 years from diagnosis overall mortality was 55%. Median EFS was 11 months for all patients. It was 7 months and 15 months respectively for children aged <3 years and >3 years (p=0.05), demonstrating a significant difference in EFS between these two age groups (Figure 5). Median OS was 9 months in those <3 years. OS could not be estimated for all patients and for those >3 years as no deaths were recorded after 14 months when greater than 50% of patients were still alive.

**DISCUSSION** CNS ATRT is a relatively uncommon tumor. Its diagnosis can be challenging as there are no clear histopathological criteria; it can resemble PNET’s, medulloblastomas and embryonal tumors. The combined cytogenetic and molecular genetic characterization of CNS ATRT’s led to the identification of a rhabdoid tumor suppressor gene in chromosome band 22q11.2. This gene abnormality is now used as a definite diagnostic tool (9,10).
The cellular origin of ATRT’s is still unknown. Inactivating mutations of the hSNF5/INI1 gene located in the chromosomal region 22q11.2 are regarded as a crucial step in the molecular pathogenesis of ATRT’s (9,10). Abnormalities of INI-1 expression have been reported to be associated with the poor outcome seen in ATRT patients (9,11).

ATRT’s are extremely aggressive tumors with most of the literature demonstrating a median survival between 11 and 17 months. More recent reports have shown some improvements in survival using newer regimens. The best therapeutic approach remains unclear, especially for younger children.

A modified sarcoma-like regimen with intrathecal chemotherapy and radiation showed promising results in a prospective multicenter study. The 2-year progression-free and OS rates were 53% and 70%, respectively. There were significant toxicities associated with this regimen and one toxic death out of 20 patients (8). Long term side effects and survival remain to be evaluated. Our one patient treated with this same approach had a good response to chemotherapy with resolution of brain involvement and stabilization of spinal disease, but developed severe debilitating post-radiation necrosis which was unresponsive to medical therapy.

High dose chemotherapy followed by stem cell rescue has shown variable outcomes (12,13). The best results have been reported by the St. Jude’s group which, in addition to radiation, gave four cycles of intensive chemotherapy followed by autologous stem cell rescue (7). One of our patients was treated using this approach and tolerated the treatment without major toxicities. She remained in complete remission until she died of an unrelated sepsis while being off therapy.

Radiation has had a significant impact on outcomes in ATRT patients. An improved survival has been seen in children treated with radiation to the craniospinal axis with or without a local boost (3). The hesitancy or inability to treat young children with radiation may account in part for the worse outcomes encountered in this age group. For example, in children less than 3 years old with medulloblastomas and gliomas, deferral of radiation in favor of other treatment modalities is recommended by most centers. However, for ATRT patients, careful consideration of radiation should be given due to the very aggressive nature of this disease. In our group, most patients received radiation irrespective of their age; however morbidity risks were thoroughly assessed on a case by case basis.

Overall, an aggressive multimodality treatment approach has provided a better survival for ATRT patients (2, 7, 8) and intrathecal chemotherapy appears to be associated with improved outcomes (3). Metastasis at diagnosis or on treatment confers a very poor prognosis. Out of 4 patients with metastasis in our series, 3 died of disease and one died of an unrelated cause.
Age is an important prognostic factor for ATRT patients. Tekautz and colleagues compared outcomes in children based on age groups and found a statistically significant difference. The 2-year EFS and OS for children aged 3 years and older were 78% and 89% respectively, compared to only 11% and 17% for those younger than 3 years (7). Our findings also support this notion, as survival for our younger patients was significantly worse.

ATRT remains an elusive form of CNS malignancy in terms of diagnosis, treatment and outcomes. The incidence of ATRT’s in our study is comparable to other reports in the literature. Furthermore, our survival data, having used a variety of treatment regimens over the past 10 years, is similar to that reported by other centers. We conclude that an intensive multimodality therapeutic approach appears to be more effective; however it is clearly associated with significant morbidity and mortality. Further studies into the physiopathology and genetic characteristics of these aggressive tumors are needed in order to develop more efficacious treatment modalities and improve the dire outcome faced by these patients.

REFERENCES
SoCIAL SERVICeS

Despite the milestones that have been made in the treatment of pediatric cancer, it remains a devastating diagnosis that affects not only the patient but the entire family. Social workers at Children’s Hospital are highly trained to assist families dealing with the diagnosis of cancer. They provide emotional support to the families; guide them through the maze of financial obligations, directing them to the most appropriate sources of monetary assistance for the child’s medical care; indicate transportation services that might be used during treatment; and help them find temporary housing while here in New Orleans, when this is suitable. They are present during the initial parent-physician conference, offering emotional or psychological buttressing in a time of extreme anxiety. Through individual and group counseling, the social workers help patients and families identify their concerns, consider effective solutions, and better cope with the child’s illness.

PsyChology

The Psychology Department provides comprehensive evaluation and management of the emotional and behavioral disorders stemming from the diagnosis of cancer. The psychologists work closely with the hematology/oncology physicians and social workers to ensure the maintenance of the mental health and stability of these patients under stressful conditions.

Psychologists also provide baseline information about the neuropsychological function of the children, whether they have a hematological or oncologic problem, something that is crucial when treatments may have a deleterious impact on their neuropsychological status. Counseling is provided for patients and families that enables them to freely discuss their concerns regarding the diagnosis, treatment, treatment aftermath, school and other social concerns.

PsyChIATry

The LSU Child Psychiatry Department has worked closely with the Hematology/Oncology Division, providing care and advisement for difficult emotional and behavioral problems. They, along with the hematology/oncology physicians and Social Services Department, have been instrumental in the organization and oversight of a pioneering multidisciplinary psychosocial conference which regularly meets to advise the hematology/oncology team on how to deal with the trauma and stress of the diagnosis of cancer, and to effectively interact with parents and patients under their care.

CIIld lIFe

Music therapists, therapeutic recreation specialists and child life specialists are available to promote a positive working relationship with children on the unit, through the use of play activities. Such activities allow each child to attain and maintain his/her maximum functional level and self-expression.

An extremely attractive playroom, with a view of an athletic field, is located on the unit. It is equipped not only with toys, but with a computer using the STARBRIGHT program which permits access to children with cancer who
are receiving care at other facilities throughout the country. The playroom philosophy is to encourage each child to make choices about their play; to foster age-appropriate developmental activities; and to help each child gain mastery, understanding and positive coping techniques regarding their particular illness through medical play. Activities may be structured or unstructured. In addition, activities available to all children within the hospital, such as movie night or bingo night, remain a star attraction for our patients with cancer. The Music, Recreation and Child Life Department is dedicated to improving the quality of life of children facing the many challenges of cancer treatment while they remain hospitalized.

**OCCUPATIONAL THERAPY**

Occupational Therapy’s involvement may include assessment and treatment of the patient’s upper extremity status (i.e., range of motion, strength, endurance), fine motor skills, visual perception, visual motor skills, and activities of daily living, such as eating, dressing, bathing, toileting and grooming.

Occupational Therapy actively promotes independence, feeling that by doing so, social and emotional needs, as well as the physical, can be effectively met.

**PHYSICAL THERAPY**

The Physical Therapy Department specializes in the assessment and treatment of gross motor function in the child with cancer. Physical Therapy is consulted on both an inpatient and outpatient basis for children who will undergo stem cell transplant, as well as for those children who might have motor deficits resulting from either primary disease or treatment effect.

**REHABILITATION MEDICINE**

The Rehabilitation Medicine team at Children’s Hospital has worked closely with the hematology/oncology physicians to provide a comprehensive approach to the treatment of patients who may have experienced a loss or impairment of functional abilities as a result of their disorder or treatment of the disorder, whether temporary or permanent. Patients with stroke in sickle cell or with hemiparesis in brain tumor are just a few of those children who have benefited from the efforts of this service. Working with physical, occupational and speech therapy services, nursing, nutritional and other services, Rehabilitation Medicine, under the guidance of Drs. Ann Tilton and Joseph Nadell, has integrated these and other services in coordinated plans intended to improve and strengthen the patient’s functional capabilities. The Rehabilitation team has organized and integrated individualized programs for each patient and has become an invaluable mainstay of treatment for the child with cancer and other hematologic disorders.

**DIETARY AND NUTRITIONAL SERVICES**

Children undergoing chemotherapy or bone marrow transplantation may suffer lack of appetite and failure to thrive. The Dietary and Nutritional Services Department at Children’s Hospital provides a complete nutritional assessment, including anthropometric and calorie/protein requirements. They work closely with the physician team, making suggestions for enteral and parenteral supplementation. Each nutritional care plan is individualized to the patient’s specific needs, with particular attention to the needs posed by a child with cancer. Parents are thoroughly counseled on diets meeting their child’s needs, whether low bacterial, low tyrosine, etc. The nutritionist assists the hematology/oncology team with assessment of daily calorie counts and provision of special instructions, when necessary. Safe food handling is emphasized for the immunocompromised patient and the nutritionist meets with the family as much as necessary to promote compliance through trust and knowledge.

**PHARMACY**

The pharmacists work closely with the physicians, nurses and other healthcare team members to provide the best possible treatment for our
patients. Not only do they prepare the therapeutic drug and advise on its administration and dosing, but they monitor patients who are on, at times, complex chemotherapeutic protocols, in order to prevent errors. They also assist the team with formulation of computer-generated orders, a practice which minimizes error. Pharmacy is actively involved in both patient and resident-fellow education, giving lectures and providing comprehensive drug information. Pharmacists work with the Quality Assurance/Improvement Department to design drug-use evaluation projects that will be administered by the Pharmacy and Therapeutics Committee.

**PASTORAL CARE**

When a child is diagnosed with cancer, the child and his/her family can experience intense and often overwhelming feelings of anxiety, helplessness, anger, guilt, fear, depression, shock and denial. Questions may be raised, such as: Why is this happening to me? Is God punishing me by causing my child to become ill? How can a loving God allow an innocent child to become so seriously ill? How am I going to get through this? Who is going to help us now?

Pastoral care services are provided to assist the child and family members as they ask these and other questions and express their feelings. The chaplain “walks with” each family, providing ministry according to the family’s spiritual needs and denomination. He listens to the stories told by each family and child and provides support where needed. He prays with the child and family when prayer is requested, and also shares joyous moments, especially when the child’s medical treatment is going well. A chaplain is on call at all times, in case of emergencies. Religious materials such as Bibles, daily meditation and Sunday services are available. The chaplain participates in weekly meetings with the staff and also participates in family conferences when asked to do so.

**VOLUNTEER SERVICES**

Volunteers work on the Hematology/Oncology unit, providing special services to the patients and their families. Volunteers usually request to work on this unit due to personal involvement with either a family member or friend who has gone through treatment at Children’s Hospital or another institution. These volunteers bring with them insight, understanding and compassion which comes from their first-hand experience. They assist Child Life staff with activities on the unit. They also spend time in the patient’s room, playing games, reading, talking or just listening to the patient. They may also relieve the parents for a short time, providing respite for them. They remain important members of the treatment team.

**STARBRIGHT WORLD**

World is a computer system with programs that help seriously ill children confront the challenges they face every day. One component of STARBRIGHT World is a private online network that connects children and teens in hospitals throughout the country. It enables young patients to share experiences, fears, frustrations and humor through Internet technologies such as Web sites, chat rooms, bulletin boards and video conferencing. Patients meet online and talk face-to-face with peers who understand the realities of living with a serious or chronic illness.

**CAMP CHALLENGE**

Children’s Hospital, along with the Cancer Association of Greater New Orleans and the Childhood Cancer Families Network, sponsors Camp Challenge, a unique, week-long camping experience geared to children with cancer and other blood disorders and their siblings. The camp is held annually in Louisiana. Dr. Jamie Morales, who serves as the co-medical director,
works with other staff, including physicians, nurses, social workers and volunteers to assure the safety of our patients. It provides recreation and the camaraderie of associating with other children who have undergone similar experiences with cancer and chronic or serious illnesses. The children look forward to the opportunity to swim, ride horseback, engage in competitive sports, and generally have a ball while forgetting the all-too-present concerns of sickness and hospital.

**RONALD MCDONALD HOUSE**

The Ronald McDonald House provides temporary residence for the families of children receiving treatment in New Orleans area hospitals. Non-resident families are given the opportunity to stay at the house, located in Mid City, New Orleans. It is a place where families can get away from the hospital, yet remain in touch with the support of hospital and medical staff within a moment’s notice. It is a home away from home for these families.

**CANDLELIGHTERS**

Candlelighters is a national nonprofit organization that provides hope, support, education, counseling and encouragement to those children and families touched by cancer. Candlelighters organizes activities and programs for families, provides psychosocial support, offers financial relief to patients’ families, and works to raise awareness of childhood cancer and related issues. The organization also produces a quarterly newspaper available at no charge for parents of children with cancer.

**A CHILD’S WISH**

A Child’s Wish is a Louisiana-based nonprofit organization that fulfills the dreams of children who are terminally ill or have life-threatening illnesses. Staffed by volunteers, this organization uses donations to enable children to achieve their wishes.

**MAKE-A-WISH**

Through its wish-granting work, the Make-A-Wish Foundation of the Texas Gulf Coast and Louisiana has enriched the lives of countless children who have life-threatening illnesses. It provides children throughout Louisiana with an opportunity to participate in activities that they might never otherwise have been able to enjoy a trip to Walt Disney World, a shopping spree, a remodeling of their room.

**OPERATION SMILE**

Children’s Hospital participates in this program with the American Cancer Society. First- and second-year medical students are partnered with cancer patients and their siblings. The purpose of the program is to allow children to have their own “buddy” who will provide emotional and psychological support, as well as friendship, and to participate with them in non-medical activities.

**CAPS FOR KIDS**

Caps for Kids is an international non-profit organization dedicated to providing headwear autographed by athletes, entertainers and other notable personalities to children, adolescents and young adults with cancer who lose their hair as a result of their treatment. Caps for Kids was founded in 1993 by Dr. Stephen Heinrich, a pediatric orthopaedic surgeon at Children’s Hospital. The program now exists at more than 70 hospitals in the United States, four in Canada, and one in Frankfurt, Germany.
Cancer Conference

AT CHILDREN’S HOSPITAL, THE CANCER CONFERENCE remains the major educational element of the cancer program. These conferences are held weekly to improve the quality of care of pediatric cancer patients through educational discussions. Children’s Hospital recognizes the importance of these multidisciplinary conferences and has been sponsoring them since 1980.

All aspects of pediatric cancer management are embraced at these conferences. Each presentation includes an outline of the medical history, physical findings, clinical and surgical course, radiological studies and pathological interpretations of each one of the cases to be discussed. An open discussion and review of pertinent medical literature follow each case presentation offering a comprehensive and multidisciplinary approach but, at the same time, tailored to the patient’s individual needs.

During 2008, a total of 46 conferences were held. On average, approximately 23 physicians, residents, students and other cancer-related supporting staff personnel attended the weekly conferences. A total of 147 cases were presented in 2008. These cases consisted of prospective, retrospective and follow-up cases. It should be noted that 97% of the cases presented were prospective and were representative of the major sites of cancer at Children’s Hospital.

All members of the medical staff are encouraged to attend and present their oncology cases at these conferences. Physicians can schedule case presentations by contacting the Hematology/Oncology Office at (504) 896-9740.
## Cancer Statistics

### Age at Diagnosis

<table>
<thead>
<tr>
<th>Age Group</th>
<th>2008 Percentage</th>
<th>2006 - 2007 Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4 yrs.</td>
<td>45%</td>
<td>35%</td>
</tr>
<tr>
<td>5-9 yrs.</td>
<td>20%</td>
<td>23%</td>
</tr>
<tr>
<td>10-14 yrs.</td>
<td>20%</td>
<td>21%</td>
</tr>
<tr>
<td>15-19 yrs.</td>
<td>15%</td>
<td>20%</td>
</tr>
<tr>
<td>19+ yrs.</td>
<td>0%</td>
<td>1%</td>
</tr>
</tbody>
</table>

### Distribution by Race and Sex

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>41%</td>
<td>38%</td>
<td>27%</td>
<td>24%</td>
</tr>
<tr>
<td>Black</td>
<td>17%</td>
<td>18%</td>
<td>13%</td>
<td>14%</td>
</tr>
<tr>
<td>Other</td>
<td>1%</td>
<td>3%</td>
<td>1%</td>
<td>3%</td>
</tr>
</tbody>
</table>

AN ESSENTIAL COMPONENT of the Children’s Hospital cancer program is the database maintained by the cancer registry. The cancer registry database, also known as the cancer data management system, is supported by IMPAC Medical Systems software program, called METRIQ. It is a system designed for the collection, management and analysis of the data on cancer patients. The information that is provided by the cancer registry is utilized in research, education and patient care evaluation. It has also proven to be of financial importance in administrative planning of allocation of hospital resources.

January 1, 1986 was established as our reference date, and as of December 31, 2008, the cancer registry has accessioned 1604 cases. A comparison of Children’s Hospital data from 2006, 2007 and 2008 is presented in the Cancer Statistics section of this report. The following discussion will focus primarily on Children’s Hospital analytic case data from 2008. In 2008, a total of 98 cases were accessioned:

- 77% (n=75) being analytic and 23% (n=23) being non-analytic.
- 60% (n=45) were male and 40% (n=30) were female.
- 24% (n=18) of our patients resided in Jefferson parish.
- The median age at diagnosis of our patients was 6.
- 41% (n=31) were white males with the highest incidence of cancer.
- 27% (n=20) were white females with the second highest incidence of cancer.
- 23% (n=17) were ALL patients which was our most common histology in 2008.

In order to evaluate cancer care outcomes, the cancer registry maintains long-term follow-up on eligible patients included in the registry. To successfully achieve survival rates the American College of Surgeons (ACoS) requires an 80% follow-up rate on eligible patients, and a 90% follow-up rate for eligible patients diagnosed within the last 5 years. The cancer registry has been able to successfully maintain the required follow-up rate.

Data is submitted to the National Cancer Data Base (NCDB) and the Louisiana Tumor Registry (LTR). In return, the NCDB provides local, state and national statistics to cancer programs that enable them to benchmark patient care and quality improvement efforts. The LTR also provides local and state statistics as a benchmarking tool for cancer programs.

Knowledgeable personnel, including at least one CTR (Certified Tumor Registrar) staff the cancer registry. The cancer registry is located in the Medical Records Department. All inquiries may be directed to Rachel Bufkin, CTR, (504) 894-5255.

<table>
<thead>
<tr>
<th>CANCER SITES</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone Marrow</td>
<td>33%</td>
</tr>
<tr>
<td>Brain &amp; CNS</td>
<td>31%</td>
</tr>
<tr>
<td>Lymph Node</td>
<td>9%</td>
</tr>
<tr>
<td>Kidney</td>
<td>9%</td>
</tr>
<tr>
<td>Soft Tissue</td>
<td>5%</td>
</tr>
</tbody>
</table>
### Analytic Cases

#### Distribution of Analytic Cases by Parish

<table>
<thead>
<tr>
<th>Parish</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acadia</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Allen</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Ascension</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Assumption</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Beauregard</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Calcasieu</td>
<td>6</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Concordia</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>East Baton Rouge</td>
<td>1</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Evangeline</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Iberia</td>
<td>1</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Jackson</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Jefferson</td>
<td>10</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>Jefferson Davis</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Lafayette</td>
<td>2</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Lafourche</td>
<td>3</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Orleans</td>
<td>4</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td>Ouachita</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Plaquemines</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Pointe Coupee</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rapides</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>St. Bernard</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>St. Charles</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>St. James</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>St. John th Baptisit</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>St. Landry</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>St. Martin</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>St. Mary</td>
<td>1</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>St. Tammany</td>
<td>4</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Tangipahoa</td>
<td>4</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Terrebone</td>
<td>2</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Vermilion</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Vernon</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Washington</td>
<td>3</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Out-of-State</td>
<td>4</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Out-of-Country</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>55</strong></td>
<td><strong>75</strong></td>
<td><strong>78</strong></td>
</tr>
</tbody>
</table>

### Cases increased 4% from 2007 to 2008

#### History

<table>
<thead>
<tr>
<th>Histology</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astrocytoma</td>
<td>3</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>Atypical Teratoid Rhabdoid Tumor</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Basal Cell Carcinoma</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Blastoma, Pleuropulmonary</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Carcinoma, NOS</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Choroid Plexus Carcinoma</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Craniohypophyrgiroma</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dermoid Cyst</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Desmoplastic Neuroepithelial Tumor</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Embryonal Carcinoma</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Ependymoma</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Ewing’s Sarcoma</td>
<td>1</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Gangliogiroma, NOS</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Ganglioneuroblastoma</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Germ Cell Tumor</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Glioma, NOS</td>
<td>2</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Hemangiosarcoma</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Hepatoblastoma</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hepatocellular Carcinoma</td>
<td>0</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>ALL(Acute Lymphocytic Leukemia)</td>
<td>9</td>
<td>17</td>
<td>17</td>
</tr>
<tr>
<td>AML (Acute myelocytic Leukemia)</td>
<td>2</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>JMML (Juvenile Myelomonocytic Leukemia)</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Hodgkin Lymphoma</td>
<td>3</td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>5</td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>Langerhans Cell Histicroytis</td>
<td>3</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Medulloblastoma</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Meningothelial meningioma</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Myelodysplastic Syndrome</td>
<td>2</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>4</td>
<td>7</td>
<td>11</td>
</tr>
<tr>
<td>Neuroectodermal Tumor, Primitive</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Olfactory Neuroblastoma</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Oligodendrogioma</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Osteosarcoma, NOS</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Peripheral nerve sheath tumor, Malignant</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Rhabdomyosarcoma</td>
<td>2</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Sarcoma</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Schwannoma, NOS</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Teratoma</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Wilms Tumor</td>
<td>2</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>55</strong></td>
<td><strong>75</strong></td>
<td><strong>78</strong></td>
</tr>
</tbody>
</table>
Community Outreach Program

Among the goals for our Community Outreach Program are the continuing efforts to educate and inform the public and health care community on the signs and symptoms as well as the incidence of cancer in children. We promote cancer prevention through presentations and discussions, encouraging adequate nutrition, sun exposure reduction (skin cancer prevention) and smoking cessation (tobacco use and cancer).

Informational sessions on cancer prevention are offered to school-aged children during their visit to Children’s Hospital. Lectures are held in the local community for schools and businesses to address the significance of cancer prevention and encourage routine medical examination for early cancer detection including breast self-exam for females and genitourinary exam for males. Brochures are available for distribution at schools, health fairs and employee fairs through the Hematology/Oncology Department. These brochures are located throughout the hospital and in satellite clinics. Information about cancer prevention and interesting links can be found on the Children’s Hospital Web site at www.chnola.org.

Hematology/Oncology Program

The Pediatric Hematology/Oncology section of LSUHSC Department of Pediatrics was formally accredited by the Accreditation Council for Graduate Medical Education (ACGME) in 1989. It remains the only accredited fellowship program between Florida and Texas. We are proud to report that, this year, despite the upheavals of the post-Katrina milieu, we again received approval from the ACGME for the fellowship. The program now directed by Dr. Maria Velez and comprised of faculty members Drs. Gardner, Morales, Singleton and Yu, continues to draw individuals from around the country and throughout the world. Graduates of the program have gone on to distinguish themselves in many fields, assuming – at times – roles of leadership wherever they have gone. The program utilizes the clinical resources and faculty expertise available at the Medical Center of Louisiana.

The program maintains an active partnership with the LSUHSC Stanley S. Scott Cancer Center. Teaching and patient care take place at Children’s Hospital. Research activities are conducted through the establishment of partnerships with experienced and capable investigators such as Drs. Augusto Ochoa, Arnold Zea, James Hempe and Lily Leiva. Electives for the fellowship are offered in blood banking, hemophilia care, radiation oncology and hematopathology. Fellows play an integral role in the planning and organization of conferences and lectures.

Teaching activities include the Cancer Conference, journal club, protocol reviews, psychosocial conferences, core lectures, and professors’ rounds. Invited speakers from many excellent institutions involved in cancer care, both local and national, help round out the fellowship’s educational opportunities.
The LaNasa Greco Center for Cancer and Blood Disorders at Children’s Hospital offers comprehensive and current therapies for the treatment of all types of malignancies and blood disorders including, but not limited to, leukemia, thalassemia, sickle cell anemia and hemophilia, among many others. In 1989, Children’s Hospital was approved as a Pediatric Hospital Cancer Program by the American College of Surgeons. Our program is affiliated with Louisiana State University’s Minority Community Clinical Oncology Program (MCCOP), which is accredited by the National Cancer Institute. Children’s Hospital is also a member of the Children’s Oncology Group (COG), a national study group of premier research institutes in the United States and Canada. Our hospital has the only approved COG bone marrow transplant program in Louisiana. Though patient care is our primary focus, Children’s Hospital is an active participant in clinical and basic research of childhood cancers and blood disorders.

Our physicians have access to the most modern therapies for treatment of malignancies and blood disorders in children. The Center for Cancer and Blood Disorders is also a teaching facility for medical students, nursing students and those completing graduate and postgraduate training. The hospital plays a major role in the training of pediatric hematology/oncology fellows. Our program is part of the LSU Health Sciences Center (LSUHSC) Department of Pediatrics and the Stanley S. Scott Cancer Center of LSUHSC.

The LaNasa Greco Center for Cancer and Blood Disorders itself had 5,723 clinic visits, 3,488 of which were for the treatment of children with cancer, and 953 for the care of sickle cell patients.
pharmacists, dieticians, laboratory technologists, and physical, occupational, speech and hearing, music and recreation and child life therapists.

**ONCOLOGY SERVICES**

**Leukemia/Lymphomas**
A full range of treatment options is available for children with acute or chronic lymphocytic and myelogenous leukemia, including chemotherapy, stem cell transplantation and radiation therapy. Oncology physicians and nurses offer and implement the treatment plan adequate for each child based on the type of leukemia, its stage and certain prognostic factors. Children with Hodgkin’s disease and non-Hodgkin’s lymphoma (NHL) are thoroughly evaluated and promptly treated according to the specific subtype and stage of the disease. They are supported by a team of psychologists, social workers and other specialized professionals who provide compassionate “total care” for the child and family.

**Soft tissue and solid tumors**
At Children’s Hospital, pediatric experts treat a variety of tumors including neuroblastoma, tumors of the central nervous system (brain and spine), soft tissue sarcoma, bone sarcoma, retinoblastoma and Wilms’ tumor. The Center for Cancer and Blood Disorders is represented by the following medical and surgical disciplines: pediatric oncologic surgery, pediatric neurosurgery, pediatric neuro-oncology, genitourinary oncologic surgery, orthopaedic oncologic surgery, pediatric ocular surgery, radiation oncology and pediatric pathology. Members of our medical team are highly skilled individuals dedicated to providing the latest innovative treatments to our young patients.

**Bone Marrow/Hematopoietic Stem Cell Transplant Program**
Hematopoietic stem cell transplantation (HSCT) has become an alternative treatment of malignant diseases for many patients. The list of diseases for which hematopoietic stem cell transplantation has been considered grows continually. The sources of stem cells are varied: bone marrow, peripheral blood stem cells mobilized by growth factors or chemotherapy, and cord blood.

The Children’s Hospital Hematopoietic Stem Cell Transplant Program began in January 1989. From January 1989 to December 2008, 239 transplants were performed. Of those transplants performed, 160 were allogeneic
and 79 were autologous. By far, the most common conditions for which HSCT has been carried out are hematologic malignancies, e.g., acute leukemia.

Diseases such as leukemia are treated at Children’s Hospital with the same protocols as those that the 240 COG institutions (i.e., St. Jude, MD Anderson, Johns Hopkins) have adopted throughout the nation. COG has recognized Children’s Hospital as the only approved bone marrow transplant site in Louisiana for COG protocol studies.

A multidisciplinary team of physicians, nurses, social workers, nutritionists, pharmacists, physical therapists, psychologists and blood bank personnel is available, with experience and commitment to the clinical practice and basic science of hematopoietic stem cell transplantation.

In July 2000, Children’s Hospital, led by Dr. Lolie Yu, became accredited by the National Marrow Donor Program (NMDP) as a transplant center. Through the NMDP, Children’s Hospital has access to the largest worldwide registry of hematopoietic stem cell donors. This affiliation provides patients with the best chance of finding a suitable donor for transplantation.

In keeping with our willingness to innovate in order to provide patients the benefit of advanced knowledge and technology, we were the first transplant center to implement the use of mesenchymal stem cells in transplantation. This procedure was performed to treat graft vs. host disease more effectively. We also were the first program in Louisiana to perform dual cord blood transplantation and have entered into a study with Celgene to perform transplants utilizing human placenta-derived stem cells in combination with cord blood stem cells.

For more information regarding the hematopoietic stem cell transplant program at Children’s Hospital, please contact Dr. Lolie Yu at the Hematology/Oncology Department at (504) 896-9740.

Children’s Oncology Group (COG)
COG is a National Cancer Institute (NCI)-sponsored cooperative group of individuals and institutions dedicated to treating cancer among children and adolescents. COG’s purpose is to: 1. improve the diagnosis and management of children and adolescents with cancer, with the aim of curing every newly diagnosed patient; 2. investigate the etiology, pathology and pathophysiology of childhood cancer; 3. assure that every child with cancer achieves the highest quality of life during and following treatment; 4. expeditiously disseminate knowledge of these objectives in all appropriate media.

Children’s Hospital and LSUHSC/Stanley S. Scott Cancer Center have been members of COG for almost 20 years. This allows the Children’s Hospital/LSUHSC Minority Community Clinical Oncology Program (MCCOP) to offer innovative and up-to-date clinical trials as part of the NCI-sponsored COG.

HEMATOLOGY SERVICES
The hematology/oncology service treats a wide variety of hematologic disorders including sickle cell disease and other anemias, neutropenias, platelet and bleeding disorders.

More children with blood disorders come to Children’s Hospital for treatment than to any other hospital in the state. They receive the highest level of care from a medical staff experienced in the latest treatments for a full spectrum of disorders.

Hemophilia and other blood disorders
Patients with hemophilia, von Willebrand’s disease, and other bleeding disorders are evaluated and treated with the most current therapies. Appropriate support for patients and parents is offered as needed. Nurse coordinators educate and coordinate the patient’s care in clinic as well as at home. We have partnered with manufacturers of Factor to secure for our patients mobile devices that permit electronic data and therapeutic management. This has allowed parents of patients with bleeding disorders to record bleeding episodes and infusion details that enable the physician to better manage the acute and
chronic complications of the disorder. We also were participants in the Hemophilia and Thrombosis Research Society Registry. The Registry provided insight into the differing management strategies employed by hemophiliacs, into the natural history of patients with inhibitors, and assessment of alternative therapies for acute bleeding episodes (NovoNordisk).

Outpatient clinic
Treatments that once required that a child be admitted to the hospital are now often given on an outpatient basis. Patients visiting the Hematology/Oncology outpatient clinic at Children’s Hospital will find themselves in a newly renovated space that provides an environment in which the comfort and care of the child and family are placed first. Located in the hospital’s Ambulatory Care Center, a separate patient suite with private entrance and waiting area has been dedicated for patients with cancer or blood disorders. The location is convenient for families and provides the safest conditions for immunocompromised patients.

Patients visiting our outpatient clinic are closely monitored by their pediatric hematologist/oncologist and nurses trained in chemotherapy administration and receive a variety of treatments, including blood transfusions, platelet transfusions and gammaglobulin infusions.

In addition to nine private rooms, there is a large treatment room (which also includes a private treatment room where stem cell or red cell exchanges can take place or patients can recover from anesthesia). In this room, patients may watch TV, play video games, or relax while watching tropical fish aimlessly wander in tanks set within the walls of the room—all this to induce a much friendlier and non-threatening environment while the child receives transfusion and other therapies.

The clinic sees on average 20 patients per day and is open Monday through Friday, 8 a.m. to 4:30 p.m.
If the need arises during a clinic visit, patients can be promptly admitted to the hospital’s acute care unit, designated specifically for hematology/oncology patients.

**Sickle cell anemia**

Comprehensive management of sickle cell disease, including transfusion therapy, skilled pain management and chelation therapy is made available at Children’s Hospital. We currently care for between 250 and 300 patients with sickle cell disease at Children’s Hospital in New Orleans. Satellite clinics are located in Baton Rouge and Lake Charles. From the time the patients are first identified as having a hemoglobinopathy, they are offered the most progressive treatment available for stroke prevention, oral chelation, retinopathy screening and monitoring for long-term complications of sickle cell disease. We have been involved in clinical trials sponsored by Novartis, Celgene and other pharmaceutical companies; this has been done to avail our patients of the newest advances in science related to this disorder, resulting in our being able to offer our patients the newest advances in the field of hemoglobinopathies as soon as they are proven safe and efficacious. In addition to sickle cell disease, we also treat individuals who are diagnosed with other hemoglobinopathies, e.g., CC Disease or thalassemia. We have explored therapeutic innovations such as non-myeloablative transplantation which offers our patients with sickle cell disease an opportunity to undergo the transplant without prohibitive risks. Our involvement in the National Marrow Donor Program and the National Cord Blood Registry permits us to offer this treatment modality to greater numbers of patients who might otherwise have had to forego this treatment option for want of an eligible donor. We are currently in an agreement with Viacord (Celgene) that will enable patients to bank cord blood—a service often beyond the financial means of many of our families.

**RESEARCH**

The members of the Hematology/Oncology section of the Department of Pediatrics (LSU and Children’s) have maintained a lively interest in research, in the effort to improve care and expand knowledge regarding the various disease processes that are encountered by them. One main venue for research has been the Children’s Oncology Group, in which all members of the division participate. Collaboration with other LSUHSC faculty and with research staff in The Clinical Trials Center has brought about exciting and fruitful results. The investigative efforts have included translational (bench to bedside) research:
1. Study of the role of the amino acid, arginine, on the cellular response of immune cells to cancer cells (Drs. Augusto Ochoa and Arnold Zea);
2. Development of an assay to determine the level of responsiveness to glucocorticoids (e.g. prednisone) in patients diagnosed with acute lymphoblastic leukemia (this testing would determine if an individual was resistant or responsive to a commonly used class of drugs used for the treatment of a spectrum of leukemia subtypes (Dr. Wayne Vedeckis);
3. Study of dendritic cells as a means of enhancing engraftment of peripheral blood stem cells and of diminishing the probability of graft-vs-host disease in transplantation recipients; and
4. Study of xenotransplantation (transplantation across species).

We have just concluded our participation in a study of the oral chelator, Exjade, which has been utilized to treat individuals with transfusional iron overload (Novartis) and continue to participate in a number of pharmaceutical company-sponsored trials, as well. They include:
1. A study of the pharmacokinetics and safety of an antifungal medication, voriconazole, in those who are immune-compromised and at high risk for the development of fungal infection (Pfizer);
2. A trial to assess the safety and efficacy of a new intravenous immunoglobulin to treat patients with immune-mediated thrombocytopenia (Grifols);
3. A trial of transplantation with umbilical cord blood from multiple donors to treat those individuals with malignant and non-malignant hematologic disorders (Celgene); and
4. The study of donepezil in children who have attention impairment after cancer therapy (Eisai).

In addition to these research efforts, the Division of Hematology/Oncology continues its clinical research efforts as a means of interesting young people, whether high school students, medical students or residents, in pursuing a career in Hematology/Oncology, both basic and clinical. Drs. Gardner and Velez have been active as mentors for the Summer Cancer and/or Genetics Research Programs offered at LSUHSC and, as such, have studied subjects such as problems had by children in school re-entry, knowledge of and acceptance of HPV vaccine, brain tumors and late effects, etc. Studies aimed at insuring quality control improvement in the hospital setting have been very important to us, with the overreaching goal of improving patient care. As an example, we have interacted with our emergency room and residency staff, emphasizing the exigency of fever in neutropenic patients and the measures which need to be taken. Through improved cooperation, enhanced educational efforts, and the use of standardized, pre-printed orders, we have greatly shortened the time that it now takes to institute care in the emergency room for patients presenting with fever and low white blood cell counts. Similarly, central line infections on the Hematology/Oncology unit now have a prevalence that is lower than the national average. Another study led to the introduction of sample labeling practices in the operating or recovery room during procedures that promise to reduce error rates. All of these studies have resulted in the institution of new interventions and ultimately, we hope, will be responsible for the improvement of patient care.

LANASA GRECO CENTER FOR CANCER AND BLOOD DISORDERS INPATIENT UNIT

The LaNasa Greco Center for Cancer and Blood Disorders opened in November 2003 on the fourth floor of Children’s Hospital. The inpatient unit boasts 18 private rooms in a state-of-the-art and comfortable environment for patients and families. Each room, as well as the entire unit, is equipped with high efficiency particle air (HEPA) filtration. The highly advanced air handling system allows bone marrow transplants to be performed in any room and is essential to reducing the risk of infection. Located away from other inpatient areas and accessed through a positive pressure vestibule, the unit allows for the highest level of protection for patients.

The unit, overlooking Audubon Park, also includes a playroom stocked with games, toys, art supplies and computers, and an activity center, where music and recreation therapists can interact with small groups of children for organized play. A parents’ lounge is available for those needing peace or respite.

When admission is indicated, an individual treatment plan for each patient is devised by pediatric oncologists, oncology nurses and other members of the multidisciplinary team. Patients and their families develop a special bond with the staff on the fourth floor and the staff is committed to helping them cope both emotionally and physically with the side effects and complications associated with disease and treatment.
Treatment Protocols

PHARMACEUTICAL TRIALS

CELGENCE CELLULAR THERAPEUTICS
Investigation of HLA-matched Related, Human Umbilical Cord Blood Transplantation for the Treatment of Symptomatic Sickle Cell Disease or Beta-Thalassemia Major in Children
A Single-Arm Study to Assess the Safety of Transplantation with umbilical cord blood augmented with human placental-derived stem cells from partially matched related donors in subjects with certain malignant hematologic diseases and non-malignant disorders

EUSA PHARMA
Usage of Erwinia Asparaginase (Erwinase Master Treatment Protocol) COG Studies

GRIFOLS PHARMACEUTICALS
A Multi-Center, Prospective, Open-Label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10 percent) in Patients with Idiopathic (Immune) Thrombocytopenic Purpura*

NOVARTIS PHARMACEUTICALS
A randomized, open-label, multi-center, phase II study to evaluate the safety and efficacy of oral ICL670 (deferansirox) 20mg/day relative to subcutaneous deferoxamine in sickle cell disease patients with iron overload from repeated blood transfusions
A one year open label, non-comparative extension to a randomized, multicenter, phase II study to evaluate the safety, tolerability, pharmacokinetics and the effects on liver iron concentration of repeated doses of 5-30 mg/kg/day of ICL670 relative to deferoxamine in sickle cell disease patients with transfusional hemosiderosis

OSIRIS THERAPEUTICS
Treatment Protocol to Evaluate Safety and Treatment Outcomes of Prochymal Infusion for the Treatment of Steroid-Refractory Acute GVHD in Pediatric Patients

PFIZER PHARMACEUTICALS
An open-label, intravenous to oral switch, multiple dose study to evaluate the pharmacokinetics, safety and tolerability of voriconazole in immunocompromised adolescents aged 12 to <17 years who are at high risk for systemic fungal infection*
An open-label, intravenous to oral switch, multiple dose study to evaluate the pharmacokinetics, safety and tolerability of voriconazole in immunocompromised children aged 2 TO <12 years who are at high risk for systemic fungal infection

All Diseases

BRAIN/CNS
ACNS02B1 Pre-Clinical Pharmacology in Surgical Brain Tumor Specimens
ACNS02B3 A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and
Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Randomized Trial
A9952 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old
A9961 A Phase III Prospective Randomized Study of Craniospinal Radiotherapy Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR or CPM, CDDP, VCR) in Children with Newly-Diagnosed Average-Risk Medulloblastoma
P9934 Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children => 8 Months and <= 36 Months with Non-Metastatic (MO) Medulloblastoma: A Children’s Oncology Group Phase III Study

CANCER CONTROL
AALL0331 Standard Risk B-Precursor Acute Lymphoblastic Leukemia, Phase III Group-Wide Study (QOL component)
AALL03N1 Understanding the Role of Adherence in the Ethnic Differences in Survival after Childhood ALL
ACCL05C1* A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Randomized Trial (QOL component)
ALTE03N1 Key Adverse Events After Childhood Cancer
ACCI0331 A Randomized Double Blind Placebo Controlled Clinical Trial to Assess the Efficacy of Traumeel (IND #66649) for the Prevention and Treatment of Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation

ALL, AML
AALL0232 High Risk B-precursor Acute Lymphoblastic Leukemia- A Phase III Group-Wide Study
AALL0331 Standard Risk B-precursor Acute Lymphoblastic Leukemia, Phase III Group-Wide Study
AALL03B1 Classification of Acute Lymphoblastic Leukemia
AALL03N1 Understanding the Role of Adherence in the Ethnic Differences in Survival after Childhood ALL
AALL0434 Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL)
AAML0531 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
ADVL04P2* A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia
ASCT0431 A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Selected Patients with CR1 and CR2 ALL
9404 Intensive Treatment for T-Cell Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin’s Lymphoma (T-Cell #4 Protocol)
9407 Induction Intensification in Infant Acute Lymphoblastic Leukemia
AAML03P1 Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ)
9904 AlinC17 Treatment of Patients with Newly Diagnosed Low Risk Acute Lymphoblastic Leukemia
9905 AlinC 17: Protocol for Patients with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study

LIVER
AEPI04C1 Low Birth Weight & Other Risk Factors for Hepatoblastoma
P9645  Phase II Protocol for the Treatment of Children with Hepatoblastoma

LYMPHOMA

AHOD0031  A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease
AHOD0431  Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low-Risk Hodgkin Disease
9425  Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study
9426  Response Dependent Treatment of Stages IA, IIA and IIIA Hodgkin’s Disease with DBVE and Low Dose Involved Field Irradiation with or without Zinecard
A5971  Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma

NEUROBLASTOMA

ANBL0032  Phase II Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
ANBL00B1  Neuroblastoma Biology Studies
ANBL00P2  Perinatal Neuroblastoma: Expectant Observation
ANBL0421  A Phase II Study of Irinotecan + Temozolomide in Children with Recurrent Neuroblastoma
ANBL0532  Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma
A3973  A Randomized Study of Purged versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High-Risk Neuroblastoma
P9641  Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma

RENAI

9442  National Wilms Tumor Late Effects Study
AREN03B2  Children’s Oncology Group Renal Tumors Classification, Biology and Banking Study
AREN0532  Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
9440  National Wilms Tumor Study – 5: Therapeutic Trial and Biology Study

SARCOMA

AEWS02B1  A Groupwide Biology and Banking Study for Ewing Sarcoma
AOST0331  A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy
ARST0431  Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma
ARST0532  Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
D9902  A COG Soft Tissue Sarcoma Biology and Banking Protocol
P9851  Osteosarcoma Biology Protocol: Companion to Group-Wide Therapeutic Studies
9354  A Randomized Phase III Evaluation of Intensified Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide, and Etoposide in the Treatment of Newly-Diagnosed Ewing's Sarcoma or Primitive Neuroectodermal Tumor of Bone or Soft Tissue. A POG/CCG Phase III Intergroup Study
D9602  Actinomycin D and Vincristine with or without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients with Low-Risk Embryonal/Botryoid Rhabdomyosarcoma: IRS-V/STS Protocol
D9803  Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine, Topotecan and Cyclophosphamide for Patients with Intermediate-Risk Rhabdomyosarcoma

**COG TRANSPLANT**
(studies are listed above)

AAML0531  A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults

AEWS0331  European Ewing Tumor Working Initiative of National Groups Ewing Tumor Studies 1999 (EURO-E.W.I.N.G. 99)

ANBL0032  Phase II Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

ANBL0532  Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma

ASCT0431  A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Selected Patients with CR1 and CR2 ALL

ASCT0521  Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation

**MISCELLANEOUS BIOLOGY/RARE TUMORS**

ABTR01B1  A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors

**NON-COG TRANSPLANT:**

**OPEN TO ACCRUAL**

National Marrow Donor Program (NMDP)/Center for International Blood and Marrow Transplant Research (CIBMTR) Research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation

A Phase I Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-malignant Disease Using a Non-myeloablative Preparatory Regimen with Campath-1H, Fludarabine and Melphalan

A Multicenter Investigation of Sibling Donor Cord Blood Transplantation for Treatment of Symptomatic Sickle Cell Disease or Beta-Thalassemia Major

High-Dose Cyclophosphamide, Carmustine and Etoposide with Autologous Bone Marrow Transplantation for Relapsed Hodgkin’s Disease

Use of High-Dose Cytosine Arabinoside (ARA-C), Cyclophosphamide, Total Body Irradiation and Marrow Transplantation as Treatment for Patients with Acute Lymphoblastic Leukemia

A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children with Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases

Selection of CD 34+ Cells for Stem Cell Transplantation of Hematologic Malignancies

Cyclophosphamide Conditioning Regimen for Marrow Transplantation from HLA Identical family Members for Severe Aplastic Anemia

NMDP/CIBMTR Research Sample Repository

Accelerating Immune Recovery Post-SCT via co-transfer of Dendritic Cell Precursors

* Protocol is currently under review by the Louisiana State University Health Sciences Center Institutional Review Board

“Studies closed to accrual” indicates that enrollment through the Children’s Oncology Group can no longer take place, but patients can continue to receive therapy according to the protocol’s guidelines, since these studies often represent the most current treatment approach available at the present time.
Publications


Crombet O, Morales-Arias J. Chronic Hypoplastic Bone Marrow in a Healthy Patient with Parvovirus B19 infection. Submitted to Southern Regional Meeting. 2007


2006


Kuvibidila S, Ode D, Warrier RP, Yu LC. In Vivo and In Vitro Secretion of Soluble Interleukin-2 Receptor (sIL2R) in Children with Acute Lymphoblastic Leukemia During the First Four Weeks of Treatment. 1


2005


2002


¹In Press
**Glossary**

**Accession:** To list in order of acquisition. An accession number is assigned to each new patient who is eligible for inclusion in the Cancer Registry database.

Allogenic: Having cell types that are antigenically distinct. In transplantation biology, denoting individuals (or tissues) that are the same species but antigenically distinct.

**American Joint Committee on Cancer (AJCC):** A committee designated to coordinate efforts of sponsoring organizations to develop staging systems for various cancers within the TNM system in the United States.

**American College of Surgeons (ACoS):** A fellowship of surgeons, organized in 1913 “to elevate the standard of surgery, to establish the standard of competency and character for practitioners of surgery,” and, in general, to assure that surgeons are properly qualified.

**Analytic Cases:** Cases that are first diagnosed and/or receive all or part of their first course of treatment at Children’s Hospital. In accordance with the American College of Surgeons guidelines for approved cancer programs, these cases must be accessioned, included in the patient index file, abstracted and followed for the lifetime of the patient by the Cancer Registry.

**Autologous:** Autogenous, related to self, originating within an organism itself.

**Class of Case:** A classification of treatment status determined by a reporting hospital. This classification is determined at the patient’s first admission. Whether a case is included in the hospital’s treatment and/or survival statistics depends upon the patient’s classification.

**Initial Therapy:** Initial definitive treatment, or series of treatments, that normally modifies, controls, removes or destroys proliferating tumor tissue. This is usually initiated within the first four months (two months for leukemia) of diagnosis. Types of initial therapy include the list below:

**Surgery:** The partial or total removal of the tumor, excluding biopsy.

Radiation: Cancer-related direct beam and non-beam therapy. Non-beam includes radium, cesium and radioactive isotopes.

**Chemotherapy:** Includes antimetabolites, alkylating agents, vinca alkaloids and antibiotics, among other agents.

**Hormone:** Includes administration of hormones/steroids, and in some cases, endocrine surgery.

**Combination Therapy:** Includes possible combinations of surgery, radiation, chemotherapy and hormone therapy.
**Immunotherapy**: Passive immunization of an individual by administration of pre-formed antibodies actively produced in an individual.

**No Treatment**: A treatment option that includes cases in which no information was available or no treatment was received.

**Non-Analytic Cases**: Cases that were not seen at Children's Hospital within the first four months following diagnosis (two months for leukemia) or who were first diagnosed at autopsy. This class of case is usually not included in a report of hospital's treatment and survival statistics. In accordance with the American College of Surgeons guidelines for approved cancer programs, these cases must be accessioned and a patient index record prepared. Although abstracting and lifetime follow-up are encouraged, these are matters of local decision by the hospital cancer committee.

**Stage**: The extent to which a primary tumor has spread from its original site. The extent of disease is determined at the time of diagnosis and/or initial therapy.

**Surveillance, Epidemiology and End Results Program (SEER)**: A registry conducted by the National Cancer Institute for the collection and analysis of data on the incidence and treatment of cancer and survival of cancer patients in the United States. A staging system was developed in 1977 by SEER and is approved for use in cancer registries by the American College of Surgeons Commission of Cancer.

**Survival**: All survival statistics were calculated using the actuarial or life-table method for observed survival rate. This method takes into account both patients with observations for varying lengths and patients lost to follow-up.

**TNM**: A staging system developed by the American Joint Committee on Cancer, in which T stands for the size of the tumor, N for lymph node involvement and M for metastasis.
Telephone Directory & Referral

Children’s Hospital Main Number (504) 899-9511
Oncology Department (504) 896-9740
Oncology Department Fax (504) 896-9758
Oncology Unit – inpatient (504) 896-9442
Oncology – outpatient clinic (504) 896-9848
Neurosurgery Department (504) 896-9568
Social Services Department (504) 896-9367
Surgery Department (504) 896-9478
Orthopaedics Department (504) 896-9569
Medical Records/Tumor Registry Administration (504) 896-9450
Diagnostic Radiology (504) 896-9565
Pathology Department (504) 896-9873

Bone Marrow Transplant Program (504) 896-9740
Lolie C. Yu, MD

Cancer Committee Chairman (504) 896-9741
Tammuella Singleton, MD

Cancer Program Liaison (504) 896-3977
Evans Valerie, MD

CANCER INFORMATION/RESOURCES

American Cancer Society (800) ACS-2345
American Cancer Society, New Orleans Chapter (504) 469-0021
National Cancer Institute 1-800-4CANCER

CANCER INFORMATION WEB SITES

American Cancer Society www.cancer.org
National Cancer Institute www.cancer.gov
Children’s Hospital, New Orleans www.chnola.org
National Childhood Cancer Foundation www.curesearch.org
Cancer Care www.cancercare.org
Cancer Survivors Project www.cancersurvivorsproject.org
National Children’s Cancer Society www.children-cancer.com
FINANCIAL
Medicaid – Enroller (504) 896-9152
Office of Family Security (504) 599-1700
Social Security (800) 772-1213
Children’s Hospital Assistance Program (CHAP) (504) 894-5166
American Cancer Society (504) 469-0021
Leukemia/Lymphoma Society (504) 887-0945
Optimist Leukemia Foundation (800) 685-9611
J.L Foundation (225) 698-1010
National Children’s Cancer Society (314) 241-1600
Cancer Recovery Fund (717) 564-4100
First Hand Foundation (816) 201-1569
Cancer Association of Greater New Orleans (504) 733-5539
Total Community Action (504) 304-6676
Kids Kicking Cancer (504) 455-7754

SUPPORT
Candlelighters (800) 366-2223
Sperm Bank Reproductive Services (504) 454-7973
Camp Challenge (504) 347-2267
Sunshine Kids (713) 524-1264
Caps for Kids (504) 891-4277

MENTAL HEALTH
Rehabilitation Program/RTC (504) 483-0415
Via Link (24 hour counseling) (800) 749-2673
Angel’s Place (Respite Care) (504) 455-2620
COPELINE - Suicide Prevention (800) 273-8255
Children’s Hospital Behavioral Health Unit, Calhoun Campus (504) 896-7200
Family Service of GNO (504) 822-0800

HOUSING
Ronald McDonald House (504) 468-6668
American Cancer Society Patrick F. Taylor Hope Lodge (504) 219-2202
Hotels – medical rates list available in Social Services Department

WISHES
A Child’s Wish (504) 367-9474
Make-A-Wish (504) 846-9474
A Special Wish (614) 575-9474

DEATH
Compassionate Friends (504) 454-5078
Seasons – The Center for Caring (504) 834-1453
St. Joseph Hospice (504) 734-0320
Serenity Hospice (504) 366-3996
A Special Thanks to our models

Jamyrah Age
Jack Anderson
Adrianna Cavanagh
Alyssa Dewease
Connor Fernandez
Maggie Hebert
Ty Inman
Laila Jacobia
Karton Jones

Vernal Morgan
Daniel Molinary
Marcus Norman
Khemani Pete
Corrina Price
Kendall Springman
Kaitlin Truxillo
Chelsie Verbene
Lauren Wright
Children’s Hospital began as a dream in the minds of a group of very special community leaders about a decade before the hospital became a reality. In the years following World War II, a poliomyelitis epidemic attacked thousands of children, leaving many handicapped. Concerns about these children led the late Elizabeth Miller Robin, a polio victim herself, to establish a rehabilitation hospital for children. The facility opened in 1955.

What makes the hospital unique is the combination of the latest developments in medical treatment and an atmosphere of love and concern for the whole child. Throughout its history, Children’s Hospital has served as a teaching facility where faculty from the Louisiana State University Health Sciences Center forms a strong pediatric teaching program. In 1976, Children’s Hospital was expanded to become a full-service general pediatric hospital. It has since expanded continually to meet the growing health care needs of our community.

Children’s Hospital is a 218-bed, not-for-profit regional medical center offering the most advanced pediatric care. It cares for children from birth to 21 years in more than 40 specialties, including life-threatening illnesses, routine childhood sicknesses and preventive care.

For more information about Children’s Hospital, call (504) 899-9511 or visit our Web site at www.chnola.org.

AFFILIATIONS AND ACCREDITATIONS
Children’s Hospital, New Orleans is affiliated, accredited or supported by the following local and national organizations:

ACCREDITATION
American Academy of Pediatrics
American College of Surgeons (ACoS) Commission on Cancer
Joint Commission on Accreditation of Healthcare Organizations (JCAHO)
National Marrow Donor Program

MEMBERSHIP
Child Health Corporation of America
Children’s Oncology Group (COG)
Louisiana Hospital Association
National Association of Children’s Hospitals & Related Institutions, Inc. (NACHRI)
Metropolitan Hospital Council of New Orleans

ACKNOWLEDGEMENTS
© Copyright 2009. Children’s Hospital, New Orleans, Louisiana. Design: Printing/Graphic Services, Children’s Hospital. The Cancer Committee would like to recognize and thank the following persons and departments for their expertise and guidance in the production of the Children’s Hospital Cancer Program Annual Report:
Tammuella C. Singleton, MD; Renée V. Gardner, MD; Lolie C. Yu, MD; Maria C. Velez, MD; Jaime Morales, MD; Mary Perrin, vice president, Hospital Operations; Robert R. Gassiot, Jr., MPS, director of Printing/Graphic Services; Wendy Huval, RHIA, director of Medical Records; Rachel Bufkin, CTR, tumor registrar; Lynn Winfield, nurse manager; Christopher Snizik, computer graphics operator; Chris Price, MA, communications manager; Hematology/Oncology Department; Medical Records Department, Public Affairs Department.